Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
European Mutual Recognition Procedure gives approval to market Aromasin
October 13th, 2005
Pfizer Inc said that it has received European Mutual Recognition Procedure (MRP) approval to market Aromasin (exemestane tablets) for a new indication, adjuvant treatment of estrogen receptor positive invasive early breast cancer following 2 to 3 years of initial adjuvant tamoxifen therapy in postmenopausal women. Aromasin is a hormonal therapy, used to treat women with breast cancers that depend on a hormone, specifically estrogen, for growth and survival. An estimated two-thirds of breast cancer cases are estrogen-dependent. The approval was based on the intergroup exemestane study (IES) that showed patients who switched to Aromasin after 2 to 3...
Source: Women's Health Weekly (2005-10-13)
|
